Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00006124
Other study ID # NCI-2009-00869
Secondary ID ID99-368N01CN851
Status Completed
Phase Phase 2/Phase 3
First received August 3, 2000
Last updated February 12, 2013
Start date June 2000
Est. completion date April 2008

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer


Description:

OBJECTIVES:

I. Compare the time to recurrence after treatment with celecoxib vs placebo in patients with superficial transitional cell carcinoma of the bladder at high risk for recurrence.

II. Correlate the modulation of one or more biomarkers with recurrence of bladder cancer and confirm the value of the marker(s) as a surrogate endpoint biomarker for bladder cancer and celecoxib.

III. Determine the toxicity of celecoxib in these patients. IV. Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and presence of Tis disease (yes vs no). Patients are randomized to one of two arms.

Arm I: Patients receive oral celecoxib twice daily.

Arm II: Patients receive oral placebo twice daily.

Treatment continues in both arms for 1-2 years in the absence of unacceptable toxicity, development of recurrent or invasive bladder carcinoma, or development of a second malignancy requiring radiotherapy or systemic therapy.

Quality of life is assessed at baseline and at week 54.

Patients are followed at 6 weeks and then every 12 weeks until the last randomized patient has been on the study for 1 year or until disease recurrence.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date April 2008
Est. primary completion date March 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Criteria:

- No concurrent radiotherapy

- No prior angioplasty

- No concurrent chemotherapy

- No concurrent oral or IV corticosteroids for more than 2 consecutive weeks or orally inhaled corticosteroids for more than 4 consecutive weeks during any 6 month period of the study

- Chronic nasally inhaled steroids allowed provided patient agrees to use mometasone or, in countries where mometasone is not available, fluticasone

- No prior coronary bypass surgery

- At least 30 days since prior investigational medication

- No other prior malignancy within the past 5 years except:

- No prior pelvic radiotherapy

- Histologically proven superficial transitional cell carcinoma of the bladder at high risk for recurrence, meeting 1 of the following staging criteria:

- Stage Ta (grade 3 OR multifocal OR at least 2 occurrences, including current tumor, within the past 12 months)

- Stage T1 (any grade)

- Stage Tis

- Patients with Ta or T1 lesions must have undergone complete transurethral resection of bladder tumor within the past 9 months

- No carcinoma involving the prostatic urethra or upper urinary tract

- Must have received the following prior to randomization:

- Induction course of BCG comprising 6 weekly intravesical doses (at least 4 doses if BCG intolerant)

- Additional induction courses of BCG allowed

- Maintenance course of BCG comprising 3 weekly doses (at least 1 dose if BCG intolerant)

- No evidence of disease by cystoscopy (with or without biopsy) and bladder cytology prior to initiation of maintenance BCG

- Concurrent interferon allowed

- Zubrod 0-2 or ECOG 0-2

- WBC at least 3,000/mm^3

- Hemoglobin at least lower limit of normal

- Platelet count at least 125,000/Mm^3

- No significant bleeding disorder

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT and SGPT no greater than 1.5 times ULN

- No chronic or acute hepatic disorder

- Creatinine no greater than 1.5 times ULN

- No chronic or acute renal disorder

- Normal kidneys and ureters on imaging study within the past 9 months

- No active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)

- No active pancreatitis

- No esophageal, gastric, pyloric channel, or duodenal ulceration that was diagnosed or treated within the past 30 days

- No history of cardiovascular disease, including any of the following conditions:

- Stroke

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other medical or psychological condition that would preclude study participation

- No hypersensitivity or adverse reactions to sulfonamides, cyclooxygenase (COX)-2 inhibitors, salicylates, or other NSAIDs

- Nonmelanomatous skin cancer cured by excision

- Carcinoma in situ of the cervix

- Stage 0 chronic lymphocytic leukemia

- Other malignancy for which patient has no current evidence of disease, has received no therapy within the past 6 months, has no concurrent or planned therapy, and has an expected disease-free survival of at least 5 years

- No concurrent immunotherapy

- At least 2 weeks since prior aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) except cardioprotective dose (no greater than 100 mg/day) of aspirin

- No concurrent chronic NSAIDs except oral cardioprotective dose (no greater than 100 mg/day) of aspirin

- Concurrent chronic use is defined as a frequency of at least 3 times per week for more than 2 consecutive weeks per year

- No other concurrent investigational drug

- No other concurrent systemic therapy

- No concurrent lithium or fluconazole

- No other concurrent hormonal therapy except hormone replacement (i.e., estrogen or thyroid hormone replacement)

- Myocardial infarction

- Angina

- Congestive heart failure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
celecoxib
Given orally
placebo
Given orally

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to recurrence 3 years No
Secondary Modulation of biomarkers 3 years No
Secondary Correlation of biomarkers with tumor recurrence 3 years No
Secondary Adverse events as measured by NCI CTC v2.0 3 years No
Secondary Quality of life as measured by EORTC QLQ-C30 v3.0 Up to 24 months No
See also
  Status Clinical Trial Phase
Terminated NCT02122172 - Afatinib in Advanced Refractory Urothelial Cancer Phase 2
Withdrawn NCT02252393 - Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer N/A
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Terminated NCT01118351 - Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer Phase 2
Terminated NCT00112905 - Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Phase 2
Completed NCT00072150 - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Phase 2
Completed NCT00407485 - VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2
Withdrawn NCT01639521 - Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Phase 2
Completed NCT00003167 - Gene Therapy in Treating Patients With Advanced Bladder Cancer Phase 1
Completed NCT00005831 - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Phase 2
Completed NCT00021099 - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Phase 2
Terminated NCT01382706 - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Phase 2
Terminated NCT00004856 - Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2
Completed NCT03174912 - In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Phase 4
Completed NCT01828736 - Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT04917809 - A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Phase 2
Completed NCT00030615 - Decitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Phase 1
Completed NCT00471536 - Pazopanib in Treating Patients With Metastatic Urothelial Cancer Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1